Capoten


Also found in: Dictionary, Thesaurus, Wikipedia.
Related to Capoten: Lanoxin, Concor

Capoten

 [kap´o-ten]
trademark for a preparation of captopril, an antihypertensive agent.

Capoten

(kăp′ə-tn)
A trademark for the drug captopril.

Capoten

a trademark for an angiotensin-converting enzyme inhibitor (captopril).

Capoten®

Captopril, see there.

Capoten

A brand name for CAPTOPRIL.
References in periodicals archive ?
Because the patent law change for Capoten and 108 other drugs would transfer enormous costs to government health programs, drug consumers will essentially pay twice: once at the pharmacy and again as taxpayers.
The United States has eight of the top-ten best sellers, including Capoten, Mevacor, and Ceclor.
pharmaceutical sales should be strong, led by Pravachol, Taxol, Glucophage and Monopril, whose gains should more than offset a sharp decline in Capoten sales.
Although patent protection on the company's Capoten, a cardiovascular medication, recently expired, there are other promising products in the pipeline.
Over a dozen companies have entered the market with generic versions of Capoten (Bristol-Myers Squibb).
The following drugs were included and are listed in the order of appearance in the journals and on the questionnaire: Voltaren, Wellbutrin, Prozac, Isoptin SR, PediaProfen, Feldene, Verelan, Capoten, Carafate, Axid, Halcion, Cipro, Calan SR, Lorelco, Procardia XL, Cardizem, Tagamet, Suprax, Kerlone, and Ventolin.
Enalapril, a copy of Merck's Vasotec, and captopril, the equivalent of Bristol-Myers Squibb's Capoten, are other generics currently available.
According to the terms of GATT, patent protection for Capoten was extended from August 8, 1995 to February 13, 1996.
s Capoten (captopril) would receive additional patent life, but its Pravachol (pravastatin sodium) would lose the additional protection.
Capoten, the company's best-selling cardiovascular drug - which was to lose patent protection in August - got a 16-month patent extension as a result of GATT.
And that includes any pending generic versions of Zantac [ranitidine HCl] and Capoten [captopril].
But Capoten (captopril), its best-selling cardiovascular drug, loses patent protection in 1995.